Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05680155 | A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients | PHASE3 | COMPLETED | 211 | — | — | Dec 29, 2022 | Oct 12, 2024 | Sep 10, 2025 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| C1-XW003 | EXPERIMENTAL | High dosage of XW003 once weekly |
| C1-Placebo | PLACEBO_COMPARATOR | Matched Placebo once weekly |
| C2-XW003 | EXPERIMENTAL | Low dosage of XW003 once weekly |
| C2-Placebo | PLACEBO_COMPARATOR | Matched Placebo once weekly |
| Name | Type | Description |
|---|---|---|
| Ecnoglutide | DRUG | Subcutaneous Injection |
| Placebo | DRUG | Subcutaneous Injection with matched volume |
Inclusion Criteria: 1. Ability and willingness to participate in the study, give written informed consent, and comply with the study specific requirements and all protocol procedures. 2. Sex: male or female; Age: 18 to 75 years, inclusive 3. BMI: 20.0 kg/m\^2 to 35.0 kg/m\^2, inclusive 4. Have been...